Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter O-CLL1-GISL study

Massimo Gentile, Giovanna Cutrona, Laura Mosca, Serena Matis, Sonia Fabris, Marta Lionetti, Fiorella Ilariucci, Simona Zupo, Caterina Musolino, Luciano Levato, Stefano Molica, Francesco Di Raimondo, Iolanda Vincelli, Nicola Di Rienzo, Emanuela Anna Pesce, Francesco Angrilli, Massimo Federico, Antonino Neri, Manlio Ferrarini, Fortunato Morabito

Research output: Contribution to journalArticle

Abstract

A risk score based on three biological features (CD38, ZAP-70, and IGHV mutational status) was previously developed to predict progression-free survival (PFS) in untreated Binet A CLL patients. Here we perform a score validation analysis in a prospective and independent cohort of patients. Biological markers (CD38, ZAP-70, and IGHV mutational status) and gene expression profiles (GEP) of leukemic cells from CLL patients included in a prospective multicenter observational study (O-CLL1-GISL protocol, clinicaltrial.gov ID:NCT00917549) were used to assess the value and reproducibility of this score. To date, 468 Binet A patients were classified as low- (0 positive marker), intermediate- (1 positive marker), or high-risk (2 or 3 positive markers) using the progression risk score. The 3-year PFS probability was 91.7%, 82.9%, and 57.4% for low-, intermediate-, and high-risk (P

Original languageEnglish
Pages (from-to)743-750
Number of pages8
JournalAmerican Journal of Hematology
Volume89
Issue number7
DOIs
Publication statusPublished - 2014

    Fingerprint

ASJC Scopus subject areas

  • Hematology

Cite this